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Abstract
Prostate cancer (PCa) is one of the most prevalent cancers among men. Early diagnosis
can improve survival and reduce treatment costs. Current inter-radiologist variability for
detection of PCa is high. The use of multi-parametric magnetic resonance imaging
(mpMRI) with machine learning algorithms has been investigated both for improving
PCa detection and for PCa diagnosis. Widespread clinical implementation of computerassisted PCa lesion characterization remains elusive; critically needed is a model that is
validated against a histologic reference standard that is densely sampled in an unbiased
fashion. We address this using our technique for highly accurate fusion of mpMRI with
whole-mount digitized histology of the surgical specimen. In this thesis, we present
models for classification of malignant, benign and confounding tissue and aggressiveness
of PCa. Further validation on a larger dataset could enable improved classification
performance, improving survival rates and enabling a more personalized treatment plan.
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Chapter 1.
1.1

Introduction

Prostate cancer (PCa) is one of the most prevalent cancers among men [1]. PCa
makes up one in five new cancer diagnoses and is the second leading cause of cancer
related death among men [1]. Initial PCa diagnosis is important to create an optimal
treatment plan for each patient. Initial diagnosis consists of a digital rectal examination,
prostate specific antigen (PSA) test, and an analysis of primary and secondary Gleason
grade, if available. Patients with a Gleason score ≤ 6, PSA < 10 and stage T1c to T2a [2]
are usually placed on an active surveillance disease management strategy, where patients
are monitored to see if the cancer becomes aggressive [2]. The T stage measures the
location and extent of PCa. T stages ≤ 2 reflect PCa that is confined within the organ.
Living with untreated cancer presents a psychological burden for some patients, resulting
in many patients choosing to undergo a procedure that may not have been needed.
Prostatectomy is a procedure consisting of the removal of the entire prostate through
surgery. Overtreatment with radical prostatectomy (RP) is estimated to occur in 20 to
60% of cases [3], resulting in significant deterioration of urinary and sexual function [3].
For a subset of patients who have localized PCa, therapies targeting PCa while
sparing healthy tissue may be an intermediate option with fewer side effects, suitable for
many patients. These therapies rely on pre-treatment target volume contours containing
aggressive PCa. Many approaches have been investigated to create these pre-treatment
target volume contours. Radiologist-identified regions from multi-parametric magnetic
resonance imaging (mpMRI) have shown promise for detection of PCa [4], but
substantial inter-observer variability in lesion contouring has been observed [5]. Many
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computer-assisted diagnosis (CAD) models have been developed to improve lesion
classification [6] [7] [4] [8] [9] . These systems can be used as second observers to
improve physician performance, especially among novice radiologists [10]. Models that
classify healthy tissue vs. malignant tissue have reached an area under the receiver
operating characteristic curve (AUC) of 0.97 in the peripheral zone (PZ) [7] [11].
However, models that classify cancer from confounding regions have had lower
accuracies, with Litjens et al. [12] achieving AUCs of 073, 0.75, 0.63, and 0.69 for
classification of tumours vs. prostatic intraepithelial neoplasia (PIN), atrophy,
inflammation and benign prostatic hyperplasia (BPH), respectively. These studies have
limitations which have made widespread clinical implementation of computer-assisted
PCa lesion characterization elusive, including small sample sizes and registration errors
in reference standards due to spatial biases. Spatial biases may be the result of falsepositive low-intensity benign regions, as low-intensity regions are indicative of prostate
cancer on T2-weighted (T2W) MRI and apparent diffusion coefficient (ADC) maps
derived from diffusion-weighted MRI, by the PIRADS guidelines [13].
Registration for CAD models is often done by radiological consensus, where
radiologists confer with each other and/or a pathologist to determine tumour location and
boundaries. This consensus mapping approach is most straightforward when identifying
true-positive mpMRI lesions corresponding to histologic foci, but identifying mpMRI
false-positive and false-negative lesions is more challenging and the attendant uncertainty
in the error in spatial mapping remains.
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Figure 1-1: Prostate zones within the prostate in the sagittal plane. PZ = peripheral zone,
CZ = central zone, TZ = transition zone, US = urethral sphincter, AS = anterior
fibromuscular stroma. (Adapted from the American college of radiology web site.)

Widespread clinical implementation of computer-assisted PCa lesion
characterization remains elusive. Critically needed is a model that is validated against a
histologic reference standard that is densely sampled in an unbiased fashion. Using our
technique for highly accurate fusion of mpMRI with whole-mount digitized histology of
the surgical specimen, we can address these biases [5].

1.2
1.2.1

Background
Prostate anatomy

The prostate is divided into 4 anatomical zones. The PZ covers 70% of the gland
and extends from the base to the apex of the prostate. The central 25% of the gland that
wraps around the urethra is the central zone (CZ). The transition zone (TZ) is made up of
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the remaining 5% of the gland. The final zone is the non-glandular anterior fibromuscular
stroma.

1.2.2

Prostate cancer epidemiology
Prostate cancer is the most common cancer identified in North American men [1].

In 2016, prostate cancer (PCa) is estimated to account for 21% of new cases of cancer
and is the second leading cause of death of cancer in men in the United States, with one
in eight men being diagnosed with PCa during his lifetime [1]. PCa progression is highly
variable [14]. The variable nature of disease progression limits treatment options to either
a radical therapy or a watch and wait strategy. 70% of cancer appears in the PZ, 25% in
the TZ and 5% in the CZ [15]. Up to 90% of patients with recently diagnosed PCa are
treated even when the disease is unlikely to have caused any major negative effects on
their quality of life [16]. Additionally, many patients who elect for a watch and wait
strategy have to endure the psychological burden of living with an untreated cancer.
Thus, a key challenge in PCa treatment selection is predicting which patients do and do
not need treatment. Computer models may have a role in addressing this challenge as
models have been shown to improve the diagnostic accuracy of PIRADS scoring when
combining the system score with a radiologist score [10], as well as classifying Gleason
grade 6 vs. Gleason grade >= 7 cancer [9, 10, 17]. Models may also be able to address
secondary objectives including accurate stratification of patients through optimized
targeted biopsy procedures, monitoring low-risk patients through longitudinal
measurements of tumour burden, and targeting curative-intent therapies for both
aggressive and less aggressive treatments.
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1.2.3

Prostate cancer diagnosis

Diagnosis of PCa follows various pathways depending on the patient’s history and
symptoms.

1.2.3.1

Lower urinary tract symptoms

If a patient presents lower urinary tract symptoms (LUTS) a primary care provider
will assess and treat the patient. PCa treatment may exacerbate LUTS, and therefore the
severity and impact on quality of life should be carefully considered before diagnosis or
treatment [18].

1.2.3.2

Unexplained symptoms

If a patient is 40 years old or older and has unexplained lower back pain with
reproducible percussion tenderness, severe bone pain, or weight loss, especially in the
elderly, they will receive a digital rectal exam (DRE) and prostate specific antigen (PSA)
test [19].

1.2.3.3

Digital rectal exam

In the context of PCa screening, sensitivity and specificity are used to measure the
fractions of positives and negatives that are correctly identified. A DRE is a procedure in
which a physician manually palpates the patient’s prostate with a gloved finger in order
to identify abnormally dense or asymmetric regions [20]. DRE has a sensitivity of 52.3%
and specificity of 83.6% [21] [22].

1.2.3.4

PSA testing

PSA is a protein primarily produced by prostate cells. PSA testing measures the
level of PSA in a blood sample. A PSA level above 10 ng/mL is considered suspicious
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for cancer. However, other conditions such as prostatitis and benign prostatic hyperplasia
(BPH) can also increase PSA levels [23]. Prostatitis comes in the form of an infection or
inflammation. Prostatitis is classified into four categories: acute bacterial, chronic
bacterial, chronic nonbacterial and chronic pelvic pain syndrome [24]. BPH is a condition
that enlarges the prostate. The enlarged prostate can squeeze the urethra, causing urinary
incontinence [25]. BPH occurs in almost all men as they age and is not considered to be a
major health concern. PSA testing has a sensitivity of 72.1% and specificity of 93.2%
[22].

1.2.3.5

Biopsy

If a patient presents with symptoms of intermediate or aggressive PCa, they will receive a
prostate biopsy. These symptoms include a PSA level > 10 and/or suspicious nodes found
during the DRE. Gleason scores are used to determine the aggressiveness of the disease.
A Gleason score is determined by inspection of architectural patterns, size and spacing of
the tumour glands [26]. During a biopsy procedure, tissue samples are taken from the
prostate through the rectal wall or less commonly through the perineum using a biopsy
needle. Biopsy can be performed using transrectal ultrasound and/or MRI for guidance
and targeting. 6–12 biopsy samples are obtained primarily in the PZ, as that is where
most cancers are found [27]. Tissue obtained from the biopsy is then examined to
determine the number of cores containing cancer and the extent of cancer in each core. A
Gleason grading system is used to identify the aggressiveness of the cancer obtained from
the biopsy [26]. The Gleason grading system is used to assign a Gleason grade to tissue
using the microscopic architecture and differentiation of prostate glands on a five point
scale [28, 29]. Grading biopsy tissue is a challenge. There is a 40% rate of discrepancy
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between biopsy and prostatectomy Gleason grade [30, 31]. By adding the primary and
secondary Gleason grades of tissue, a Gleason score can be obtained. Many studies have
used the Gleason score for classification of tissue.

1.2.4

Prostate cancer treatment
Once a patient has been diagnosed with prostate cancer, an appropriate treatment

plan will be selected with assistance from their physician. Treatment options will vary
depending on the risk level associated with a particular patient.

1.2.4.1

Watchful waiting and active surveillance

Watchful waiting (also referred to as conservative management, expectant
management and deferred treatment) is a palliative disease management strategy for
monitoring patients while not treating them [2]. Active surveillance is intended as a
curative disease management strategy that initiates curative treatment if and when
necessary [32]. In active surveillance, patients are closely monitored for signs of
progression that include frequent biopsies and PSA tests [33]. If progression is suspected,
these patients can proceed to radical treatments [33]. Active surveillance is recommended
for patients who have low-risk cancer. Low risk cancers have a Gleason score ≤6,
PSA<10ng/ml and clinical stage T1c–T2a [33].

1.2.4.2

Prostate-focused therapies

Radical prostatectomy and radical radiotherapy are the main treatment choices for
localized prostate cancer. These treatment methods treat the entire prostate to the same
degree. Radical prostatectomy is a procedure where the entire prostate is removed
through surgery. Radical prostatectomy is used to treat patients with cancer that does not
extend beyond the prostate capsule. The primary side effects of a radical prostatectomy
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include high rates of erectile dysfunction (34–90% [34, 35]), urinary incontinence (8–
13% [34, 36]) and other complications (10–30% perioperatively and 4–10% within a
year [34, 37]). Radiation therapy can refer to multiple procedures that irradiate the
prostate in order to damage DNA. The first type of radiation is external beam radiation
therapy (EBRT). This is a procedure in which high energy x-rays generated outside the
body are focused on the prostate from multiple angles. A second type of radiation therapy
is low-dose-rate brachytherapy (BT). This is a procedure where radioactive seeds are
permanently inserted into the prostate. High-dose-rate BT is another type of radiation
therapy where a highly radioactive emitter is moved within the prostate during the
procedure and then removed. Radiation therapy patients have high rates of erectile
dysfunction. A meta-analysis of patients with localized PCa who underwent radiotherapy
found the probability of maintaining erectile dysfunction after treatment was 80%, 69%,
68%, 22%, 16% and 13% for BT alone, BT + EBRT, EBRT alone, nerve sparing RP,
standard RP, and cryotherapy, respectively [35]. Brachytherapy resulted in urinary
incontinence in 6.6% of men after the procedure. For external beam radiation, minor to
moderate urinary symptoms were present in 30% of men.

1.2.4.3

Lesion-focused therapies

In order to reduce the side effects of radical therapy, emerging treatments that
preferentially target the prostate cancer lesions are being investigated. These treatments
may allow for strategically escalating treatment to tumours in patients to achieve better
outcomes.
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1.2.4.3.1

Whole-gland radiation with focal boost

A local recurrence may occur in the prostate after a radical radiotherapy, typically
at the site of the dominant lesion [38]. Technological advances for planning and
delivering radiation enable radiation oncologists to deliver different doses to specific
regions within the prostate [39, 40].

1.2.4.3.2

Prostate-sparing and lesion-only therapies

Although prostate cancer is multifocal in 67–82% of patients [41-43], there is a
subset of patients who have a dominant lesion surrounded by non-cancerous tissue. There
is also evidence that the size of the largest cancer focus is the primary predictor of risk of
recurrence and biochemical failure, even in multifocal prostate cancers [43]. These
findings have led to the development of treatment methods that target the cancer while
sparing outside healthy tissue. Some of these treatment modalities include high-intensity
focused ultrasound [44], cryotherapy [45], photodynamic therapy [46], laser ablation [47]
and radiation therapy [48]. Early evidence from studies of several focal therapies
suggests that they successfully reduce the side effects prevalent in radical therapies [4951]. Cryotherapy studies have reported incontinence rates lower than 5% and erectile
dysfunction rates of 10–35% [45]. High-intensity focused ultrasound studies have
reported incontinence rates less than 10% and erectile dysfunction rates of 5–11% [52]. A
recent consensus panel suggested that delineation of cancerous regions should be
performed using mpMRI [53]. These suggestions imply prostate cancer imaging and
lesion delineation could play an important role in focal therapy planning.
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1.2.5

Prostate cancer imaging
There are many methods of imaging used to aid in PCa diagnosis and treatment

planning. The focus of this thesis is on mpMRI for lesion classification.

1.2.5.1

Magnetic resonance imaging

MRI is used to provide rich anatomical and functional information. It allows for
control of contrast using different acquisition sequences. MRI is being used in many
areas of PCa diagnosis. Detection [13], staging [54, 55], localization [56-58], therapy
planning [40, 53, 59], and therapy monitoring [60] are all areas where localized prostate
cancer treatment and planning have been improved.
Inter-observer variability in localization of prostate cancer on MRI is very large
[53]. The following sections describe sequences and imaging protocols that have been
investigated for imaging localized prostate cancer.

1.2.5.2

T2W MRI

T2-weighted MRI is used to visualize the structural components of the prostate.
T2-weighted MRI measures the transverse relaxation due to the dephasing of atomic
nuclei. In the PZ, tumours appear hypo-intense relative to benign peripheral zone tissue
[61]. Tumours in the central gland are generally homogenous with low-intensity, illdefined irregular boundaries, and a lenticular shape [62]. Figure 1.2(a) shows a T2W
MRI of a prostate, with a hypo-intense region in the PZ (indicated by an arrow) showing
a cancerous lesion.

11

b) ADC MRI

a) T2W MRI

Figure 1.2: (a) T2W MRI of a prostate, showing a cancerous lesion as a
hypointensity (arow) in the PZ. (b) ADC map of the same slice, showing the lesion
as hypointensity (arrow).

1.2.5.3

Diffusion-weighted MRI

Diffusion-weighted (DW) MRI is used to measure the rate of diffusivity of water
molecules in tissue. In tumours, diffusivity drops due to the increased cellular density
associated with cancer [63]. DW MRI post-processing is used to create apparent diffusion
coefficient (ADC) maps computed from multiple DW MR images taken with different bvalues [13]. A b-value measures the strength and timing of the gradients used to generate
the images. Higher b-values represent a stronger diffusion effect. S0 is the MR signal at
baseline, D is the diffusion coefficient and the signal, (S) after diffusion gradients have
been applied is given by:
S = S0 e−bD

(1)

Prostate cancer appears hypo-intense on ADC maps. DW MRI has been shown to have
higher sensitivity for central gland tumours compared to other MRI sequences [63, 64].
ADC values have also been shown to be correlated with Gleason score [65-67]. The main
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limitation of DW MRI is low resolution, [13, 63] but ADC also suffers from distortion
artifacts [68, 69]. Figure 1.2(b) shows an ADC map of the same slice of the prostate as
shown in Figure 1.2(a), with a hypo-intense region in the PZ (indicated by an arrow)
showing a cancerous lesion.

1.2.5.4

Dynamic contrast-enhanced (DCE) MRI

DCE MRI is used to detect changes in vascular characteristics associated with
angiogenesis due to cancer [70, 71]. A DCE MRI pulse sequence rapidly images the
patient using a sequence of T1-weighted MR images prior to and for 5-10 minutes after
introducing a gadolinium-chelate contrast agent. DCE MRI creates contrast based on how
quickly the contrast agent washes in and out of tissue. In cancerous tissue, the contrast
agent washes in and out faster than in non-cancerous tissue. Pharmacokinetic parameters
can be modelled by combining faster sequences with estimates of the arterial input
function [70, 71]. Pharmacokinetic parameters such as the contrast transfer coefficient
ktrans and the rate constant kep can be used to detect the presence of cancer [72]. Patient
motion is the main challenge for DCE MRI. Secondary challenges include the presence
of confounding non-cancerous abnormalities that mimic cancer, such as prostatitis in the
peripheral zone, and highly vascularized BPH in the central gland [71].

1.2.5.5

MR spectroscopy

MR spectroscopy (MRS) is an imaging method that measures concentrations of
metabolites that can be distinguished by the resonance frequencies of their protons. These
protons include choline, creatine, and citrate [73]. Elevated choline and decreased citrate
are typically found in cancerous tissue. Choline and creatine are difficult to separate from
each other [70], so a (choline+creatine)/citrate ratio is used for diagnosis. This ratio has
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been shown to be correlated with Gleason score [74]. MRS interpretation is challenging
because of contamination of the signal from nearby lipids, high sensitivity to shimming,
operator variability, and common abnormalities that mimic cancer such as inflammation
and BPH [70, 72, 73, 75].

1.2.5.6

Transrectal ultrasound

Transrectal ultrasound (TRUS) imaging is used mainly to estimate prostate
volume and for image guidance during biopsy and needle-based therapy procedures.
TRUS imaging allows for rapid visualization of the prostate gland and the boundary
between prostate zones. However, the sensitivity for detecting prostate cancer on TRUS
is low at 31% [76-79].

1.2.5.7

Histology in prostate cancer

A histological examination is used at several points in the clinical workflow. Histological
examination of biopsy tissue is used to follow up on initial detection in screening
populations, for ongoing monitoring in active surveillance and to confirm recurrence in
post-treatment populations. Histological examination is also used to assess prognosis for
patients post-prostatectomy [80], and to inform decisions about adjuvant therapy [81].
The Gleason grading system categorizes tissue based on its microscopic morphological
appearance including glandular differentiation and growth patterns within the stroma.
The system can be used to measure the aggressiveness of a particular tissue which has
been shown to correlate with patterns on mpMRI.
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a)

b)

c)

Figure 1.3: (a) Whole-mount digitized histology, (b) Pathologist
contours, (c) masks derived from whole-mount digitized histology.

1.2.6

Computer-aided diagnosis systems for cancer
Computer-aided diagnosis (CAD) techniques have been investigated for many

types of cancer diagnosis. These types include breast [82, 83], lung [84-86], and
colorectal [87]. CAD techniques for PCa have not been investigated until recently [88].

1.2.7

Prostate CAD systems
The first model was proposed by Chan et al. in 2003 [89]. Since then, there have

been over 50 studies proposed for various tasks related to PCa diagnosis. Table 1.1
shows the main studies and their principal characteristics. The first row of the table
describes the work presented in this thesis. Note that it is distinguished from all of the
other studies in the table because it classifies malignant, benign, and confounding tissue
and high and low Gleason grade on T2W and ADC MRI which has not been done before.
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Table 1.1: Summary of CAD systems with some of their defining characteristics:
probabilistic neural network (PNN), linear discriminant analysis (LDA), support vector
machine (SVM), Markov random field (MRF), random forest (RF), naive Bayes (NB),
decision stump (DS), logistic regression (LR), artificial neural network (ANN), quadratic
discriminant analysis (QDA), cross validation (X-val), leave-one-out (LOO), Wilson
rank-sum (WRS), MRI modalities (Mods) regions of interest (ROIs) malignant (M),
benign (B), confounding tissue (C), radiologist false positives (RFP), biopsy (B), wholemount digitized histology (WM), whole-mount digitized histology registration with
quantified registration error (WMQ) and guided biopsy (GB). The first row of the table
describes the work presented in this thesis.
Author

Year

Soetemans
Ampeliotis
[8]
Ampeliotis
[90]

2016

Classifiers
SVM,
KNN

X-val

Accuracy

k-fold

AUC 0.96

2008

PNN

LOO

2007

PNN

LOO

AUC: 0.9
AUC: 0.87,
0.84

Antic [91]

2013

LDA

LOO

AUC: 0.94

Artan [92]

2010

SVM,
MRF

LOO

Sen: 0.66,
Spe: 0.74

Artan [93]

2009

SVM,
MRF

LOO

Sen: 0.74,
Spe: 0.82

Chan [89]

2003

LDA, SVM

LOO

AUC: 0.84

Giannini
[94]

2015
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Reference standards
There are five general categories for reference standards. (1) Standard clinical

practice for biopsy uses TRUS targeting and TRUS guidance to deliver needles in a
sextant arrangement through the prostate [132]. This is the least accurate reference
standard because ultrasound is inferior to MRI for targeting and guidance [133]. (2) The
second category of reference standards uses MR targeting and TRUS guidance to aim
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needles at suspicious areas [134-136]. This technique can be improved using fusion
guided biopsy, a technique in which pre-biopsy MRI are fused with real-time TRUS
images [137]. This method improves accuracy but does not allow for confirmation of
needle placement because the biopsy is taken prior to the scan to confirm placement
[137]. (3) MR guidance can be used with MR targeting to improve biopsy needle
placement further as MR guidance allows for confirmation of needle position. (4) Transperineal mapping (TPM) is the most accurate biopsy-based reference standard. TPM
takes many samples from the prostate that are projected into a single 2-dimensional plane
to get an accurate representation of the prostate [138]. Ideally, each sample is processed
and stored separately to allow for accurate location information of any tumour(s).
Biopsies are small cylindrical samples of tissue (~18 mm in length and 1 mm in
diameter) [139]. These tissue samples are used to determine if cancer is present. (5)
Whole-mount histological sections is the final and most accurate reference standard. A
histological examination is a readily accepted reference standard used to verify the
presence, location and grade of prostate tumours. This examination refers to a
pathologist’s inspection of tissue on a microscopic level to identify tissue properties from
a ~4-µm-thick section. Whole-mount sections are typically registered to mpMRI by
radiologist/pathologist consensus mapping.

1.2.9

Image preprocessing
CAD systems generally include a preprocessing step to normalize the MR data or

to transform the data into a specific domain. Inter-image variability is large, even when
the same protocol and same scanner is used. Noise filtering, bias correction and signal
intensity standardization are the three main groups of pre-processing methods for prostate
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CAD [88]. Noise filtering is used to correct for noise is caused by inhomogeneity in the
main magnetic field during an MRI acquisition [88]. The simplest type of noise filtering
is median filtering [109]. However; since the noise follows a Rician distribution, median
filters are not well formalized to address the noise distribution in MR images [88].
Wavelet-based filtering is a common approach used to address this limitation [6] [109].
Bias correction techniques are used to correct the inhomogeneity of the bias field.
Parametric and non-parametric methods are used to correct for the smooth variation of
the signal intensity throughout the image [7] [124]. When using an endorectal coil, a
hyper-intense signal around the coil appears. This can make segmentation and
registration more challenging [140] [141].

1.3

Feature extraction

Discriminative features can be used to identify PCa. Choosing the right features for a
classifier is more important than choosing the classifier itself [142]. First order features
include basic statistics measures such as mean, median and percentiles. These features,
illustrated in Figure 1.4, are good for identifying basic differences such as hypo-intense
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regions; however these features do not take into consideration spatial distributions.
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Figure 1-4: Histogram showing some common first order texture features.
Second order texture features look at a neighbourhood of pixels in order to
measure differences in spatial distributions of pixels. These features can identify
differences first order features miss, as illustrated in Figure 1.5.

a)

b)

Figure 1-5: Two images with the same mean intensity of 0.5 but
second order energy of 0.309 and 0.5 for a) and b) respectively.
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1.3.1.1

Statistics-based features

The most common approach can be classified as statistical methods, or first order
texture features [88]. A feature map is first computed for the whole image. Statistics are
extracted from regions of interest (ROIs).

1.3.2

Intensity-based features
PCa can be detected using MRI signal intensity data. They are one of the most

common features used in CAD systems. In order to mitigate inter-scan variability in MR
images, signal intensity standardization is often done. Litjens et al. [4] used the MR
signal equation, the proton density image and a reference tissue to estimate a T2-estimate
map.

1.3.3

Edge-based features
Edge based features can be created by convolving the original image with an edge

operator. There are three main types of edge operators: Prewitt, Sobel, and Kirsch [4].
Prewitt and Sobel operators are linear edge detectors that compute a discrete
differentiation operator to find an approximation of the gradient of the image intensity
function. Kirsch operators are a non-linear edge detector that finds the maximum edge
strength in a few predetermined directions. A Gabor filter is another linear filter that uses
frequency and orientation representations that are similar to those of the human visual
system.

1.3.4

Texture-based features

Radiomics is emerging as an area of study that looks to extract additional information
from medical images [143, 144]. Radiomics aims to enable more personalized treatment
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for patients by tailoring their treatment based on predicted response on pre-treatment
imaging features [145]. Radiomics depends on quantitative image feature analysis, which
involves the extraction of measurable texture information from an image. Second-order
and third-order features can be extracted in many ways, including statistical methods,
structural methods, model-based methods and transform-based methods [146]. Statistical
texture analysis uses high-order statistics of an image intensity histogram. A grey-level
co-occurrence matrix (GLCM) can be used to calculate GLCM texture features by
analyzing neighbouring pixel pairs. The GLCM C, defined over an n × m image I,
parameterized by an offset (Δx, Δy) can be defined as

C∆x,∆y (i, j) = ∑np=1 ∑m
q=1 {

1.3.5

1, if I(p, q) = i and I(p + ∆x, q + ∆y) = j
. (1)
0, otherwise

Haralick features
The GLCM is typically large and sparse, and therefore various metrics of the

matrix can be taken to generate a more useful set of features [147]. These features include
contrast, correlation, sum of squares, inverse difference moment, sum average, sum
variance, sum entropy, entropy, difference variance, difference entropy, measure of
correlation 1 and 2 and maximum correlation coefficient. Contrast is a commonly used
texture feature that is measured by
N −1

N

N

g
g
g
∑n=0
∑j=1
n2 {∑i=1
C(i, j)} , |i − j| = n, (2)

where Ng is the number of gray levels in the image. Correlation and homogeneity are also
commonly used in CAD systems. Correlation can be calculated as
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∑i ∑j(ij)C(i,j)−μx μy
σx σx

, (3)

where μx , μy , σx , and σx are the means and standard deviations of px and py, the partial
probability density functions.

1.3.5.1

Fractal analysis

Cancerous tissue shows a higher fractal dimension than healthy tissue. A fractal
dimension is a ratio providing a statistical index of complexity comparing how detail in a
pattern changes with the scale to which it is measured. To estimate the fractal dimension,
a wavelet-based method in a multi-resolution framework can be used as reported by
Lopes et al [6]. Lv et al. [7] calculate texture fractal dimension (TFD) as a geometric
description of image textures. TFD is computed using

TFD = lim

logNs
1

, (4)

s→0 log(s)

where s is the box size and Ns is the number of the boxes with size scale s.

1.3.5.2

Wavelet-based features

Wavelet filter decomposition approaches are used to extract fine structural image
detail at different orientations and scales [123]. This may prove useful in quantitatively
characterizing micro and macroscopic visual cues radiologist use when identifying PCa
[123]. The integral wavelet transform is defined as

[Wψ f](a, b) =

1

∞

∫ ψ
√|a| −∞

From this, the wavelet coefficients cjk are given by

(x−b)
a

f(x)dx. (5)
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cjk = [Wψ f](2−j , k2−j ), (6)
where a = 2-j is called the dyadic or binary dilation and b = k2-j is the dyadic or binary
position.

1.3.5.3

Anatomical-based

In order to account for anatomical features, some studies use the relative distance to the
prostate boundary as a feature. The relative position features in x, y, and z directions are
also used as features. The relative position features are calculated as
B(x) = min d(x, y), (7)
y∈Pb

where x is the position of a voxel, d is the Euclidean distance operator, P is the set of
prostate voxels and Pb is the set of prostate boundary voxels. Litjens et al. [4] also used
PZ probability features including intensity, texture and anatomical features to generate a
likelihood map for each voxel belonging to the PZ [4]. The relative distance is computed
as

RD(x) =

B(x)
max B(x)

. (8)

y∈Pb

They also measure the relative position using
xi −min xi

RP(xi ) = max x y∈P
. (9)
−min x
y∈P

i

y∈P

i
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1.3.5.4

Percentiles

Percentiles are the most widely used statistic [88]. Percentiles can be manually or
automatically set by observing the distribution to find the best discriminant value for
differentiating malignant vs. healthy tissue [88].

1.3.5.5

Statistical moments

Statistical-moments are basic statistics such as mean, standard deviation, kurtosis
and skewness. These features are included in many studies.

1.3.5.6

Histogram-based

Liu et al. introduced four types of histogram-based features [148]. The first
corresponds to the histogram of the signal intensity. The second is the Histogram of
Oriented Gradient (HOG) [148]. The HOG uses the distribution of gradient directions to
describe local shape. The third type is shape context which is a way to describe the shape
of an object [149]. The last type use the Fourier transform of the histogram created via
Local Binary Pattern (LBP) [150]. Kwak et al. [97] use LBP by generating a binary
pattern code
p−1

LBPP,R = ∑p=0 s(Gp − Gc )2p , (10)
where c is a given center pixel, s(x) is 1 if x ≥ 0 and 0 if x < 0, gc and gp represent the
gray level of the centre pixel and its neighbourhood pixels p(p=0,…,P-1), and R is the
radius of the neighbourhood.
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1.3.6

Feature selection
Feature selection is used in CAD models because exhaustive search of high-

dimensional feature spaces is infeasible due to computational limitations. There have
been several feature selection methods used in CAD systems. Feature selection
techniques can be categorized into feature selection and feature extraction. There are
three main types of feature selection categories: filters, wrappers and embedded methods
[151].

1.3.6.1

Filters

Filters type methods select variables using criteria that are independent of the model.
They use general features such as correlation and mutual information. Filters are fast but
they ignore feature dependencies. Niaf et al. [107] use a filter method that uses a twosample t test to reduce the feature space. Mutual information was introduced by [107] to
select a subset of features. Maximum relevance and minimum redundancy were
introduced by Peng et al. [112], as another approach to find independent features.

1.3.6.2

Principal component analysis

Principal component analysis (PCA) is a statistical technique used to reduce
dimensionality [152]. PCA computes the covariance matrix for the full data set to reduce
the data while preserving relevant information. The input image, X, can be transformed
using a set of p-dimensional vectors of weights
w(k) = (w1 , … , wp )(k) , (11)where p is the number of columns. The first component can
be computed by
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wT XT Xw

w(1) = arg max {

wT w

}. (12)

Further components can be found by subtracting the first k-1 principal components from
X and then finding the loading vector which extracts the maximum variance from the
new data matrix

w(k) = arg max {

̂T
̂
wT X
k Xk w
wT w

}. (13)

Multiple linear regression methods such as ridge regression, canonical correlation
analysis and principal component regression are also used in CAD systems.

1.3.6.3

Laplacian Eigenmaps

Laplacian Eigenmaps is a non-linear method that builds a graph from
neighbourhood information. These Eigenmaps try to find a low-dimensional space in
which the proximity of the data should be preserved from the high-dimensional space.

1.3.6.4

Local linear embedding

Local linear embedding (LLE) is a widely used technique that attempts to
discover nonlinear structure in high dimensional data. LLE maps its inputs into a lower
dimensional single global coordinate system. Tiwari et al. [9] used a bagging approach
with multiple neighbourhood sizes for detection of PCa.
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1.3.7

Classifier Performance
There are several machine learning algorithms used in CAD systems. See Table

1.1 for an overview of CAD system performance and methodologies.

K=7
Figure 1-6: SVM (left), and KNN (right) decision boundaries.

1.3.7.1

Rule-based methods

The first group of CAD systems use rule-based methods with labels of cancerous
or benign to classify malignant vs. healthy tissue [7]. With unsupervised classification,
clustering methods have been used to classify tissue without using labels [107].

1.3.7.2

Linear methods

Linear model classifiers such as linear discriminant analysis (LDA) optimize
linear separation between two classes [153]. A popular choice among studies is the use a
SVM. A SVM is desirable because it maximizes the margin between classes, improving
classification performance (Figure 1.6 left). A separating boundary takes the form
{x ∈ χ|w T x + b = 0} (14)
where given a training dataset of n samples {(x, y1 , … , (xn , yn ))} ⊂ X x Y, where X is the
feature space and y is the two-class labelling, Y = {-1, +1}. To achieve a separation
boundary an optimization problem is created by combining a minimum norm objective
function and classification constraints. The optimization problem is used to classify a test
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vector by computing sign(f(x)) where f(x) represents the signed distance to the margin
and can be expressed as
f(x) = ∑i=1…n αi yi xiT x + b. (15)

1.3.7.3

Non-linear methods

Non-linear models are commonly used to improve accuracy at the cost of
additional time and complexity. K-nearest neighbours (KNN) is a non-parametric method
that uses the votes of its neighbours for classification, where the classification is done by
choosing the result as the majority of the neighbours (Figure 1.6 right). Quadratic
discriminant analysis is non-linear and can be used instead of LDA [154]. SVMs can be
nonlinear by using a nonlinear mapping function to map the data to a higher dimensional
space, where the data is linearly separable. Probabilistic classifiers have also been
investigated as a nonlinear method of classification. Probabilistic classifiers include the
naïve Bayes model, which is commonly used [106] [155].

1.3.7.4

Artificial neural networks

An artificial neural network (ANN) is a network inspired by biological neural
networks. ANNs are an interconnected group of nodes with an input, hidden and output
layer [131]. Probabilistic neural networks are another type of network that can be
modelled by changing the activation function of the hidden layer. Probabilistic feedforward neural-networks have also been investigated [111].

1.3.7.5

Ensemble classifiers

Ensembles combine many weak classifiers that perform slightly better than
random to produce one strong classifier. Ensemble learning classifiers include AdaBoost,
random forest and probabilistic boosting tree [6], [156], [117]. Graphical model
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classifiers such as Markov random fields have been used for classification and to segment
lesions in mpMRI [102], [157].

1.4

Thesis hypothesis and objectives

To take a meaningful step toward addressing the unmet clinical need to provide
accurate and personalized assessment, the main objective of this thesis is to create a
computer-aided system for classification of malignancy and Gleason score using a highly
accurate imaging-histology registration method to generate a reference standard. The
central hypothesis of the thesis is that a CAD system that uses a highly accurate reference
standard for training can provide accurate and reliable classification and diagnosis of
localized prostate cancer. This system will use SVM and KNN machine learning
algorithms to classify regions using texture features derived from mpMRI. These
algorithms were chosen based on their compatibility with smaller sample sizes, ease of
interpretation and performance among relevant literature for PCa classification. The two
primary objectives of this thesis are to:
1) Develop and validate a method for classification of malignant, benign and
confounding tissue on mpMRI using first and second order texture features with a SVM
and KNN machine learning algorithm.
2) Develop and validate a method for classification of high and low Gleason grade
tumours on mpMRI using first and second order texture features with a SVM and KNN
machine learning algorithm.
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Chapter 2.

2

Computer-Assisted Characterization of Malignancy and
Gleason Grade of Prostate Cancer on Multi-Parametric MRI
The contents of this chapter are in preparation for submission to the Medical Physics
journal: D. Soetemans, G. S. Bauman, E. Gibson, M. Gaed, J. A. Gomez, M. Moussa, J.
L. Chin, S. Pautler, A. D. Ward. Characterization of Malignancy and Gleason Grade of
Prostate Cancer on Multi-Parametric MRI.

2.1

Introduction

Prostate cancer (PCa) is one of the most prevalent cancers among men [1].
Treatment selection depends on risk stratification, which in turn requires an estimate of
tumour stage and grade. In the hands of highly-skilled readers, multi-parametric magnetic
resonance imaging (mpMRI) has shown promise for detection of PCa, [2-6] but
substantial inter-observer variability in lesion contouring has been observed [7].
Improving lesion classification performance may lead to a reduction in overtreatment of
PCa [8] [9, 10] by improving differentiation between indolent and aggressive tumours
[11].
Computer-assisted diagnosis (CAD) models have been investigated to improve
classification of malignancy and Gleason grade. These models use a radiomics-based
approach, which refers to using a comprehensive set of quantitative image features to
determine clinical parameters of interest based on imaging features [12]. This approach
may enable more personalized treatment for patients, as radiomics have been investigated
as a method to determine a relationship between imaging appearance and tumour
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phenotypes [13]. Clinical evaluation of a CAD model has shown that differentiation
between benign and aggressive PCa improves when combining the CAD prediction with
a radiologist’s Prostate Imaging – Reporting and Data System (PIRADS) score,
especially among novice radiologists [14].
Many models have been validated using histology obtained from biopsies that are
preferentially guided toward suspicious regions identified on mpMRI, [15], [16], [17],
[18], [19]. Such validation may be impacted by sparse and spatially-biased sampling and
biopsy localization uncertainty in image registration techniques. Spatial biases may be the
result of false-positive low-intensity benign regions, as low-intensity regions are
indicative of prostate cancer (although not uniquely so) on T2-weighted (T2W) MRI and
apparent diffusion coefficient (ADC) maps derived from diffusion-weighted MRI, by the
PIRADS guidelines [2]. Cancers are also often under-graded based on transrectal
ultrasound (TRUS)-guided biopsies, [20] with the rate of discrepancy between the
Gleason grade at biopsy and the true grade at prostatectomy estimated to be 40% [21].
Many recent models use post-radical prostatectomy (RP) histologically verified
lesions mapped to mpMRI by radiologist-pathologist consensus [22], [6]. This consensus
mapping approach is most straightforward when identifying true-positive mpMRI lesions
corresponding to histologic foci, but identifying mpMRI false-positive and false-negative
lesions is more challenging and the attendant uncertainty in the error in spatial mapping
remains. There have been several reports of previous work suggesting that CAD models
may be promising for PCa classification on mpMRI. CAD models have achieved an area
under the receiver operator curve (AUC) of 0.97 for the differentiation of PCa from
benign tissue [23] [24]. Many recent studies have focused on a more difficult
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classification task involving differentiation of prostate cancer from confounding
abnormalities such as radiological false positives, prostatic inter-epithelial neoplasia
(PIN), atrophy, inflammation, and benign prostatic hyperplasia [25], [22], [26].
However, these studies have limitations which have made widespread clinical
implementation of computer-assisted PCa lesion classification elusive, including small
sample sizes and registration errors in reference standards due to the aforementioned
spatial biases and localization errors.
Critically needed is a model that is validated against a histologic reference
standard that is densely sampled in an unbiased fashion. We address this using our
technique for highly accurate fusion of multi-parametric MRI (mpMRI) with wholemount digitized histology of the surgical specimen [27]. This study investigates the use of
supervised machine learning for 1) classification of malignant and benign tissue, 2)
classification of malignant and confounding tissue (i.e. false positive regions identified
by radiologists), and 3) classification of high (Gleason grade > 3) and low (Gleason grade
3) tumours, using first and second order texture features extracted from mpMRI.

2.2

Materials and methods

Patient selection and image acquisition
As part of a clinical trial we obtained prostate specimens from 22 subjects who
underwent radical prostatectomy with the following inclusion criteria: (1) male, (2) age
18 years or older and (3) clinical prostate cancer stage T1 or T2 with histological
confirmation from biopsy. The exclusion criteria were (1) prior therapy for prostate
cancer, (2) use of 5-alpha reductase inhibitors within 6 months of the study start, (3)
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inability to comply with pre-operative imaging, (4) allergy to contrast agents, (5) sickle
cell or other anemias, (6) hip prosthesis, (7) sources of artifact within the pelvis and (8)
contraindications to MR imaging. The research was approved by our institutional human
subjects research ethics board and informed consent was obtained from each subject.
Imaging
Prostate mpMRI were obtained 19 ± 8 weeks (mean ± SD) after biopsy and 2 ± 1 weeks
(mean ± SD) before surgery using a Discovery MR750 (GE Healthcare, Waukesha, WI,
USA) at 3 Tesla with an endorectal coil (Prostate eCoil; Medrad, Warrendale, PA).
Clinical T2W protocol used repetition time (TR) 4000-13000 ms, echo time (TE) 156164 ms, bandwidth 31.25 kHz, 2 averages, field of view (FOV) 14 cm x 14 cm x 6.2 cm,
slick thickness 3.3-3.6 mm, slice spacing 3.3-3.6 mm, 128 x 256 matrix size, 20-43 slices,
flip angle 90°. Clinical DWI protocol used repetition time (TR) 4000 ms, echo time (TE)
70-77 ms, bandwidth 125 kHz, 3 averages, field of view (FOV) 14 cm x 14 cm x 6.2 cm,
slick thickness 2.2 mm, slice spacing 2.2 mm, 320 x 192 matrix size, 40 slices, flip angle
90°. After prostatectomy, two sets of strand-shaped fiducials were added, running from
base to apex [7]. Internal fiducials were made from cotton thread infused with a 1:40
solution of gadopentetate dimeglumine and blue Tissue Marking Dye (Triangle
Biomedical Sciences, Durham, NC). Surface-mounted fiducials were made using animal
tissue infused with a 1:40 solution of gadopentetate dimeglumine and 10% buffered
formalin. This process resulted in seven surface-mounted fiducials and three internal
fiducials [7]. The specimen was then immersed in Christo-Lube (Lubrication
Technology Inc., Franklin Furnace, OH, USA) to provide a black background and
minimize boundary artifacts on imaging. Ex vivo imaging used a T1-weighted protocol
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[3D spoiled gradient recalled sequence, TR 6.5 ms, TE 2.5 ms, bandwidth ± 31.25 kHz,
eight averages, FOV 14 cm × 14 cm × 6.2 cm, slice thickness 0.4 mm, 256 × 192 matrix,
312 slices, flip angle 15°, duration 25 min] and a T2-weighted protocol (3D fast spin
echo sequence, TR 2000 ms, TE 151.5 ms, bandwidth ± 125 kHz, three averages, FOV
14 cm × 14 cm × 6.2 cm, slice thickness 0.4 mm, 320 × 192 matrix, 312 slices, duration
25 min). Histology images and contours were registered to mpMRI by registering the
histology to ex-vivo 3D MRI using 10 fiducial markers [28, 29] followed by semiautomatic registration of the ex-vivo MRI scan and the MRI scans to a high resolution in
vivo 3D T2W MRI. The histology to ex-vivo registration was performed using an affine
transformation utilizing the spatial information provided by the 10 fiducial markers [7].
The ex vivo-to-in vivo MRI registration was performed using a thin-plate-spline warp
technique aligning anatomic landmarks [7]. Landmarks were identified along the prostate
border, peripheral zone, urethra and verumontanum, as well as corresponding benign
prostatic hyperplasia nodules and cystic spaces to warp each digital histopathologic
image to its corresponding in vivo MR imaging plane. Average 3D registration error,
measured using intrinsic landmarks, was ≤ 2 mm [7].
Image pre-processing
Spatial T2W signal variation due to endorectal coil sensitivity was mitigated using the
N4ITK image bias correction algorithm [30] implemented in Slicer 4.2 (Surgical
Planning Lab, Harvard Medical School, Boston, USA). Inter-patient differences in T2W
MR image intensity were accounted for by scaling the intensities such that the mean
signal in manually segmented periprostatic fat regions, as indicated by a graduate student,
matched an arbitrary reference value across patients.
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Pathologist Contouring
After standard whole-mount paraffin embedding, a 4-μm-thick section was cut from each
midgland tissue block and stained with hematoxylin and eosin. The resulting slides were
digitized on a ScanScope GL (Aperio Technologies, Vista, CA, USA) bright field slide
scanning system with a 0.5 μm pixel size. A pathologist contoured and graded all
cancerous regions, as well as a prostatic intraepithelial neoplasia (PIN). The images and
contours were then downsampled to 30 μm/pixel. The Gleason grade is used to measure
the aggressiveness of cancer [31].
Radiologist Contouring
Four observers read the mpMRI scans independently and blinded to histopathology.
These observers included one radiology resident and three radiologists, with 5, 6, 2.5 and
2.5 years of prostate MRI assessment experience, respectively. Their performance is
illustrated in Table 2.2. Observers used the PIRADS guidelines to identify equivocally,
likely or highly likely cancerous lesions (i.e. PIRADS scores 3-5) on mpMRI and then
delineated them on the unregistered T2W and ADC images separately.
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Table 2.2: Radiologist true positives and false positives at
different PIRADS thresholds. R1-R4 indicates the four
radiologists.
Radiologist
ADC TPs ADC FPs T2W TPs T2W FPs
R1 PIRADS 5
11
4
9
10
R1 PIRADS ≥ 4
22
24
15
16
R1 PIRADS ≥ 3
25
35
19
32
R2 PIRADS 5
22
22
22
26
R2 PIRADS ≥ 4
31
31
33
38
R2 PIRADS ≥ 3
36
65
36
52
R3 PIRADS 5
11
11
14
20
R3 PIRADS ≥ 4
17
27
21
33
R3 PIRADS ≥ 3
25
39
28
50
R4 PIRADS 5
2
2
13
22
R4 PIRADS ≥ 4
22
32
14
36
R4 PIRADS ≥ 3
22
34
15
38
Zonal Segmentation
The peripheral zone (PZ) and central gland (CG) were delineated manually by a graduate
student using the T2W MR images. Separating the prostate into the PZ and CG has been
previously shown to increase classification accuracy [3] [32].
Tumour Size Filtering
Some of the tumour regions on histology were separated by a small amount, creating
small islands of cancer foci. To connect these islands, the histology contours were first
rasterized to binary images with pixel size matching that of the mpMRI (0.2743
mm/pixel). Next, a disk-shaped structuring element with a radius of 2 pixels (0.55 mm)
was used to expand all the tumour regions by morphological dilation on the mpMRI
images. The islands were then eroded using the same structuring element. Analysis was
performed on all remaining tumours having a longest diameter of ≥ 1.5 mm.
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Feature extraction
We calculated 22 first order statistical features to analyze image intensity. See
Table 2.3 for the full list of texture features, where g(i, j) refers to the GLCM, HX and HY
are entropies of g x and g y , HXY = − ∑i,j g ij log 2 g ij , HXY = − ∑i,j g ij log 2 {g x (i)g y (j)},
HXY = − ∑i ∑j g x (i)g y (j)log 2 {g x (i)g y (j)}, μ refers to the mean, x̃ refers to the
median, σ refers to the standard deviation, and N refers to the number of pixels. The
GLCM neighbourhood voxel distance was 0.2743 μm (1 voxel), and texture features
were averaged over all four directions.

a)

b)

c)

d)

Figure 2.6: Illustration of extracted ADC texture features
showing: a) energy, b) entropy, correlation and contrast
calculated using a square window with a length and width
of 2mm centered on each voxel.
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Table 2.3: First and second order texture features used in this study.
First-Order Features
Second-Order Features
Mean
1
∑x
N i i

Variance

GLCM Contrast

GLCM Variance

1
∑ (x − μ)2
N−1 i i

∑ |i − j|2 g(i, j)

∑ (i − μ)2 g(i, j)

Standard
Deviation

Entropy

GLCM Dissimilarity

∑ (x − μ)2
√ i i
N−1

− ∑ IP log 2 IP

∑ |i − j|g(i, j)

Energy

Uniformity

GLCM Energy

∑ xi2

∑ IP 2

∑ g(i, j)2

i

i,j

i,j

max(g(i, j))

i,j

i

GLCM Inverse Variance
∑

i,j

i

GLCM Entropy
Median

GLCM Max Probability

GLCM Sum Average

1 Percentile

2N

− ∑ g(i, j) log 2 g(i, j)

∑

i,j

i=2

GLCM Autocorrelation
Maximum

i,j

90 Percentile

2N

−∑
i=2

GLCM Homogeneity 1
g(i, j)
i,j 1 + |i − j|

GLCM Homogeneity 2

Maximum
− Minimum

99 Percentile
∑

Mean Absolute
Deviation

GLCM Correlation
Mean Gradient Value

1
∑ |x − μ|
N i i

(i − μi )(j − μj )g(i, j)

∑

σi σj

i,j

Root Mean
Square

GLCM Cluster Prominence
Variance of Gradient

1
√ ∑ xi2
N i
Kurtosis

g(i, j)
2
i,j 1 + |i − j|

∑i,j ((i − μi ) + (j −
4

Bimodality Coefficient

log 2 [g x+y (i)]g x+y (i)

GLCM Sum Variance
2N

∑
Range

ig x+y (i)

GLCM Sum Entropy

10 Percentile
∑ ijg(i, j)

Minimum

g(i, j)
2
|i
i,j − j|

∑
i=2

i2 g x+y (i)

GLCM Difference Entropy
N−1

−∑
i=0

log 2 [g x+y (i)]g x+y (i)

GLCM Information Measure
Correlation 1
Hxy − Hxy1
max[HX, HY]

GLCM Information Measure
Correlation 2

μj )) g(i, j)

√1 − exp[−2(HXY2 − HXY)]

GLCM Cluster Shade

GLCM Diagonal Moment
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1 ∑i(xi − μ)2
N
σ4

Skewness 2 + 1
3(N − 1)2
Kurtosis +
(N − 2)(N − 3)

∑i,j ((i − μi ) + (j −

Skewness

Median Absolute
Deviation

GLCM Cluster Tendency

1 ∑i(xi − μ)3
N
σ3

1
∑ |x − x̃|
N i i

∑i,j ((i − μi ) + (j −

3

μj )) g(i, j)

2

μj )) g(i, j)

1
∑ √ |i − j|g(i, j)
i,j 2
GLCM Inverse Difference
Moment
∑

g(i, j)
2
i,j 1 + (i − j)

GLCM features can characterize anatomical structures, homogeneity, and grey-level
transitions. During feature selection, training set positive or negative samples were
duplicated to ensure the ratio of positive to negative samples was 1:1. This is done to
discourage the classifier from choosing a decision boundary with an unbalanced FPR and
FNR. Features were rescaled to range from 0-1.
Feature selection
Each region of interest in our dataset is characterized by an 88-dimensional point in
texture feature space. Therefore, exhaustive search of the feature space to find the
optimal feature subset is not feasible due to computational limitations. A forward feature
selection method was used with 10 repetitions of randomized cross validation to
sequentially add the feature that increased classification accuracy the most, using the
same classifier as used in subsequent the machine learning step.
Machine Learning
A support vector machine (SVM) classifier was used for each experiment. A
SVM maps vectors from the input space into a high dimensional feature space. A kernel
function is used to determine the mapping. It finds a linear decision rule in the form of an
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optimal separating boundary that has the widest margin between the decision boundary
and the input vector. A decision boundary takes the form
{x ∈ χ|w T x + b = 0}, (16)
where given a training dataset of n samples {(x, y1 , … , (xn , yn ))} ⊂ χ x Y, and where χ is
the feature space and Y is the class labelling, Y = {-1, +1}. An objective function takes the
form
min
d

1

w∈R ,b,βi ∈R 2

‖w‖2 + C ∑ni=1 βi, (17)

which is constrained by
yi(w T xi + b) ≥ 1 - βi, i = 1,…,n (18)
0 ≤ βi, i = 1,…,n
where C is the cost coefficient that weights the classification error and βi correspond to
the distance to the margin for possibly misclassified samples xi. This optimization
problem can be expressed as
1

max − 2 ∑ni=1 ∑nj=1 αi αj yi yj xiT xj + ∑ni=1 αi , (19)
αi ∈R

where αi are the Lagrange multiplier coefficients and which is constrained by
∑ni=1 αi yi = 0. (20)
0 ≤ αi, ≤ C

i = 1,…,n

A test vector is then classified by computing sign(f(x)), where f(x) represents the signed
distance to the margin and is expressed as
f(x) = ∑i=1…n αi yi xiT x + b, (21)
where the sign of f(x) is used to determine the classification and the distance to the
margin is used as the classifier’s confidence. All results with the SVM were obtained
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using the PRTools library [33]. A support vector machine maximizes a margin for
classification.
KNN is a non-parametric method that uses the votes of its neighbours for
classification, where the classification is done by choosing the result as the majority of
the neighbours. Default parameters were used for each classifier. For the SVM the
default kernel was linear. K is the number of neighbours voting and is optimized with
respect to the leave-one-out error on the training dataset, which is performed during each
fold of cross validation.

2.3

Results

This section presents the performance of the system for the SVM and KNN algorithms.
For each experiment, 4-fold cross validation was used to measure the AUC, FPR and
FNR.
Classification of Tumours and Benign Tissue
Our first experiment uses a design similar to several studies that classify malignant and
benign tissue [34, 35]. Table 2.4 shows the results of the experiment. In total, 69 tumours
and 44 benign tissue regions in the PZ, and 23 tumours and 22 benign tissue regions in
the CG were used. Benign tissue regions were created by selecting a region from the
contralateral side of the prostate when possible for each prostate slice. The imbalance of
tumours to benign tissue is due to prostate slices where there was little or no benign tissue
region available for a benign sample. Note that we were able to achieve an AUC of 0.96
in the PZ using a SVM, which is competitive with the highest reported among the
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literature. Also note that performance in the CG was lower than the PZ, which agrees
with evidence presented in relevant literature [3] [32].
Table 2.4: Classification of malignant and
benign tissue.
Classifier

Zone

AUC

FPR

FNR

SVM

PZ

0.96

0.05

0.19

CG

0.75

0.24

0.43

PZ

0.94

0.13

0.14

CG

0.75

0.23

0.37

KNN

Classification of Tumours and Radiologist False Positives
The second experiment focused on classification of malignant and confounding
tissue, in the form of radiologist false positives. The results are illustrated in Table 2.5.
Post-RP histologically verified tumours were used as positive samples and radiologist
false positives were used as negative samples. Sixty-nine tumours and 102 radiologist
false positive regions in the PZ and 23 tumours and 52 radiologist false positive regions
in the CG were used in this experiment. We were able to achieve an AUC of 0.89 and
0.88 in the PZ using the SVM and KNN algorithms, respectively. These accuracies are
comparable to other studies that use a similar setup to classify malignant tissue and
confounding pathologies such as prostatic intraepithelial neoplasia, atrophy, benign
prostatic hyperplasia and inflammation.
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Table 2.5: Classification of malignant and
confounding tissue in the form of
radiologist false positives.
Classifier

Zone

AUC

FPR

FNR

SVM

PZ

0.89

0.10

0.29

CG

0.84

0.21

0.23

PZ

0.88

0.05

0.23

CG

0.71

0.22

0.45

KNN

Classification of High and Low Gleason Grade
Our third experiment involved characterizing tumours with a Gleason grade of 3
and tumours with a Gleason grade >= 3+4. Table 2.6 illustrates the results for this
experiment. 29 malignant regions had a Gleason grade >= 3+4 and 49 malignant regions
had a Gleason grade of 3. We were unable to achieve high accuracies for this experiment,
highlighted by an AUC of just 0.48 for the KNN in the PZ. Other studies have reported
success using the ADC maps to classify high and low Gleason scores [36] [35] .

Table 2.6: Classification of high and low
Gleason grade.
Classifier

Zone

AUC

FPR

FNR

SVM

PZ

0.60

0.44

0.49

KNN

PZ

0.48

0.35

0.77
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2.4

Discussion

Our results demonstrate that the CAD system can classify malignancy of PCa with an
AUC accuracy of 0.96. Comparing our system to previous systems suggests that a highlyaccurate fusion of histology with mpMRI is important for classification accuracy, as this
system enables clean samples for both malignant and benign regions of interest for model
training. Using our system for highly-accurate registration we were able to achieve an
AUC of 0.96 using a SVM algorithm for classification of tumours and benign tissue in
the PZ. This performance is competitive with the top performing models that have an
AUC of 0.97. Our results for classification in the PZ and CG agree with current published
literature which indicates that classification in the CG is more difficult than the PZ. [32]
Many recent studies have focused on classification of tumours and confounding
structures. Our results agree with the current literature which has found that this is a
much more difficult task compared to classification of malignant and benign tissue.
Litjens et al. [22] achieved AUCs of 073, 0.75, 0.63, and 0.69 for differentiation of
tumours vs. PIN, atrophy, inflammation and BPH, respectively. Some studies also look at
classifying tumours vs. radiologist false positives [24] [36]. Vos et al. were able to
achieve an AUC of 0.82. Using our approach for classification of malignant and
confounding tissue in the form of radiologist false positives, we were able to achieve an
AUC of 0.89 in the PZ using the KNN algorithm. To our knowledge, this is the highest
reported accuracy in the literature for this type of classification. Table 2.2 illustrates the
false negatives and false positives of the radiologists for contouring PCa at different
PIRADS thresholds. Radiologist performance was moderate, suggesting the model may
improve classification accuracy when used as a secondary observer. Accuracy results for
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classification of high and low Gleason grade were lower than seen in the literature. We
suspect this is due to two main reasons. The first is that our sample size of high Gleason
score tumours was small as there were very few prostates in our dataset with a Gleason
score > 3+4. The other reason we suspect our accuracy was lower is due to spatial biases.
Unlike many studies, our dataset was not retrospectively annotated after analyzing
histology results. Looking at our radiologist annotations on the ADC maps shows spatial
bias in the form of incorrectly extending tumour boundaries to include hypo-intense
benign tissue in some cases. This may explain why our accuracy for high and low grade
was lower than other studies in the literature.
Our study has some limitations. First, our study consisted of patients who were
treated with radical prostatectomy, inducing a selection bias. Although prostatectomy is
reserved for patients with aggressive PCa, our data included a large number of Gleason
score 6 regions and few with a Gleason score >= 4. This may explain why our
performance for detecting aggressive prostate cancer was low. Second, a small sample
size of 22 patients was used. Further validation in a larger dataset with more high grade
cancer is required for advances in accuracy.

2.5

Conclusion

We have developed a CAD system for classification of suspicious prostate tissue.
The systems performance for classification of malignant and benign tissue in the PZ is
competitive with the highest reported among the literature. Our system also achieved a
high accuracy rate when characterizing malignant and confounding tissue in the form of
radiologist false positives. This research supports the development of a clinical CAD
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system in the form of a radiological tool for improved diagnosis and patient treatment
planning.
There are several potential usage scenarios for our system. The first would be to
use the system as a second observer for radiologists during screening. This could reduce
the workload of radiologists as multiple opinions are often given during screening. This
system could also help with patient risk stratification by suggesting whether a suspicious
area is high or low grade cancer. This allows for more informed physician decisions and
may allow for reduced overtreatment.
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3

Chapter 3.

Discussion and conclusions
The final chapter of this thesis reexamines the research objectives and provides
the key findings and conclusions. This chapter also addresses limitations of the current
study and the field, and the potential solutions for both. Finally, future directions for PCa
detection and diagnosis are presented.

3.1

Contributions of the thesis

This thesis contributes advances in methods, concepts and knowledge in several
key areas.
Methods: CAD systems can be difficult to compare due to differences in datasets and
design. Many of the top performing models focus on classification of tumours vs. healthy
tissue ([1] [2]), however, a more clinically relevant CAD system would classify tumours
vs. confounding regions. Some recent studies have investigated classification of these
confounding pathologies, including radiologist false positives, prostatic inter-epithelial
neoplasia (PIN), atrophy, inflammation, and benign prostatic hyperplasia [3], [4], [5].
Our study measured the performance for both classification of benign tissue and
confounding tissue in order to enable a more complete breakdown when comparing
models. The approach presented in this thesis is the first ever to classify malignant and
confounding tissue using first and second order texture features derives from mpMRI,
validated using a highly accurate registration algorithm for fusion of histology to
mpMRI.
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3.2

Validation

Previous CAD systems used radiological consensus for registration of histology to
mpMRI for validation. The consensus technique can lead to spatial biases in the form of
false-positive low-intensity benign regions, as low-intensity regions are indicative of
prostate cancer on T2W and ADC MRI. Our system is the first to use a densely-sampled
unbiased reference standard derived from a registration of histology images to MR
images with < 2 mm target registration error [6]. Rather than relying on biases in
radiologist consensus mapping, this reference standard enables us to generate highquality unbiased contours for our samples when training our model.
Knowledge: Using a SVM for classification of malignant and benign tissue in the PZ we
were able to achieve an AUC of 0.96. This is competitive with the highest reported AUC
among the literature. Using a SVM for classification of malignant tissue and confounding
tissue in the form of radiologist false positives we were able to achieve an AUC of 0.89.
To our knowledge, this is the highest reported accuracy among the literature. Our system
had poor performance for classification of high and low Gleason grade. Although other
models have been shown to have moderate success for this type of classification, our
results suggest there is a significant amount of room for improvement for this type of
classification.

3.3

Limitations

Our study has several limitations. First, our study consisted of patients who were
treated with radical prostatectomy, inducing a selection bias. In a clinical setting, patients
would have a range of outcomes from completely healthy to having an advanced form of
prostate cancer. Our study focused only on patients who were scheduled for radical
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prostatectomy, ensuring at least one tumour was present per patient. However, even with
this selection bias, many of our patients had a low Gleason grade cancer. This distribution
of aggressiveness plays into our favour, as many of the patients we analyzed could have
been candidates for a focal therapy. A second limitation of our study is a small sample
size of 22 patients that was used. Further validation in a larger dataset is required because
prostate cancer will have a different appearance based on a number of factors such as
zone of origin, geographical location, age, and genomic makeup. In order to properly
classify each type of tumour, two approaches may be appropriate. The first approach to
this problem would be to build a global dataset with a large number of samples that is
available to validate models with. However, this approach may be incredibly expensive
and time consuming due to all of the preparation work and collaboration that would be
required. A second approach to fix a small sample size would be to investigate ways of
extracting and registering information from previously processed prostates. There are
large repositories of prostates and prostate cancer that could be tapped into in order to
expand the size of the dataset. A major limitation inherent to all CAD systems is the lack
of an understanding of what causes the expression of texture features. Lalonde et al. have
looked at analyzing a genomic classifier in order to understand which genes can be used
to predict biochemical recurrence and metastasis [7]. An understanding of these
mechanisms is critical in order for CAD system to proceed to clinic, as it would eliminate
the black box approach currently taken. This in turn may increase the confidence and
optimism of physicians and radiologist to use such a system.
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3.4 Future Directions
The methods developed in this thesis support many research initiatives in several
directions. This section addresses remaining gaps in knowledge that exist and potential
applications of this system on future directions.

3.4.1 External validation
CAD systems have been shown to improve radiologist performance with
detection and diagnosis. However, prior to clinical validation, multiple large independent
datasets must be used to validate such tools. External validation is important because it
ensures models are not overfitted to their data. In most previous publications, CAD
systems were validated using cross validation. Although this is seen an appropriate
approach, a more rigorous approach would be to have a training set, a testing set and
validation set. A validation set is not common with CAD models because it requires
further division of the samples which are usually very limited. Such validation may
provide additional information to improve assessment and provide personalized treatment
plans for patients.

3.4.2 Incorporation of additional knowledge
This thesis has suggested that an accurate histology to MR registration system for
detection and diagnosis of PCa may improve accuracy. There remains room for
improvement for both PCa detection and diagnosis. Our models have focused exclusively
on using imaging features to classify tumours and suspicious regions. Incorporating
patient characteristics such as age, family history, PSA level, etc. may improve
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performance and better inform physicians for treatment planning, although this presents
various challenges. These challenges include maintaining patient confidentiality,
obtaining the data, and quantifying the data. Radiomic features are quantitative and
continuous, but clinical data can be qualitative or discontinuous. Data can take the form
of binary decisions (i.e., does the patient have a history of PCa) or a scale (i.e., a rating of
1-5 stars). Data in this form may influence classifiers to behave in an unpredictable
fashion, particularly when the sample size is low, as each additional training sample
could maximally move the decision boundary in one direction. Characteristics such as
patient genomics and family history also may be inaccessible or challenging to obtain.

3.4.3 Decision Support
The impact of using a CAD system to aid a physician with detection and
diagnosis may be in the ability to provide more personalized treatment plans for patients.
Litjens et al. have shown that when a CAD system is used as a secondary observer,
radiologist classification performance improves, especially among novice radiologists
[8]. Completely automatic CAD systems have also been investigated [9] [10]. Various
approaches can be taken to generate contours around suspicious regions. Giannini et al.
created a fully automatic CAD system for peripheral zone lesions that used a voxel-wise
malignancy probability map to create regions by keeping pixels with a probability higher
than 60% to be malignant. Litjens et al. have used a Hessian blob detector approach to
generate initial regions of interest [9]. Additional research on automatically generating
regions of interest that are suspicious for PCa may further improve the performance of
these systems.

73

3.2 Conclusions
Although CAD models have made significant improvements, tough challenges
still remain.
Working in a high dimensional feature space requires the use of feature selection
techniques in order to determine the optimal feature set. There are several feature
selection methods used in the literature, such as forward feature selection, reverse feature
selection and branch and bound feature selection. There are several reasons different
techniques are employed including time taken and complexity of the method. Further
research is required in order to compare and contrast the different techniques to
determine their optimal use.
Several machine learning classifiers have been used to characterize and classify
tumours. Each of these classifiers have advantages and disadvantages associated with
them. For example, a support vector machine can be advantageous for classification as it
maximizes the margin between two classes of points. This improves accuracy but is much
slower, and thus is only beneficial with a small number of samples.
Confounding regions have overlapping appearance to prostate cancer and can
mask the appearance of cancer. Texture feature extraction may allow for better
assessment of cancer from confounding regions to assess the subtle differences. Studies
have looked at characterizing tumours vs. radiological false positives, prostatic interepithelial neoplasia (PIN), atrophy, inflammation, and benign prostatic hyperplasia [3],
[4], [5]. Further investigation of classification of confounding regions may improve
overall performance.
In conclusion, we created a CAD system for classification of malignant, benign
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and confounding tissue as well as low and high Gleason grade, validated using our
method for highly accurate fusion of mpMRI with whole-mount digitized histology of the
surgical specimen. Our system is competitive with the highest reported accuracy among
the literature for classification of malignant and benign tissue. Our system exceeded
reported accuracies for classification of malignant and confounding tissue in the form of
radiologist false positives. In order to further improve CAD systems, classification of
confounding regions should be a primary area of focus.
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